188440-97-3

Upstream product

• 52605-49-9 sarcosine ethyl ester hydrochloride 
• 7115-91-5 2-ethoxycarbonylbenzyl bromide 
• 13200-60-7 Sarcosine ethyl ester 
• 1531-78-8 o-(chloromethyl)benzoic acid ethyl ester 

Downstream Products

• 109568-41-4 3-ethoxycarbonyl-4-hydroxy-2-methyl-isoquinolinium; picrate 
• 102081-00-5 3-(4-dimethylamino-benzylidene)-2-methyl-2,3-dihydro-1H-isoquinolin-4-one 
• 101434-99-5 2-methyl-2,3-dihydro-1H-isoquinolin-4-one-phenylhydrazone 
• 101441-62-7 3-benzylidene-2-methyl-2,3-dihydro-1H-isoquinolin-4-one 
• 113258-90-5 4-hydroxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 113454-58-3 2-methyl-4-phenyl-1,2-dihydro-isoquinoline 
• 550-44-7 N-methylphthalimide 

Relevant academic research and scientific papers

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.